Download PDF
Klin Padiatr 2000; 212(2): 47-52
DOI: 10.1055/s-2000-9651
ÜBERSICHT

Georg Thieme Verlag Stuttgart ·New York

Inhalative Stickstoffmonoxidtherapie bei Frühgeborenen

Inhaled nitric oxide in preterm neonates:T.  Hoehn1 , M.  F.  Krause2 , C.  Bührer1
  • 1Klinik für Neonatologie, Charité, Virchow-Klinikum, Humboldt-Universität, Berlin
  • 2Neugeborenen-Intensivstation, Universitäts-Kinderklinik, Freiburg
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Zusammenfassung:

Die Therapie der persistierenden pulmonalen Hypertension des Neugeborenen (PPHN) mit inhalativem Stickstoffmonoxid (iNO) zählt nach Veröffentlichung einer Reihe von randomisierten und kontrollierten Studien mittlerweile zu einem etablierten Verfahren in der neonatologischen Intensivmedizin. Ganz anders ist die Situation beim Frühgeborenen, da infolge der Interferenz von Stickstoffmonoxid mit der Thrombozytenaggregation das Risiko von intraventrikulären Blutungen bzw. deren Ausprägungsgrad unter dieser Therapie als risikoreicher eingeschätzt wird. Die bisher vorliegenden Studien bei Frühgeborenen beantworten die Frage nach der Inzidenz von intraventrikulären Blutungen (IVH) nur unzureichend, Endpunkte sind in den meisten Fällen Veränderungen der Oxygenierungsparameter. Mittlerweile konnten zwei größere Studien von iNO bei Frühgeborenen zeigen, dass diese Therapieform nicht mit einer erhöhten Hirnblutungsrate im iNO-Kollektiv assoziiert ist. Weitere randomisierte, kontrollierte Studien zum Einsatz von Stickstoffmonoxid bei Frühgeborenen sind dringend erforderlich um den künftigen Stellenwert dieser Therapieform und deren Indikationen zu determinieren.

According to a number of recently published, randomized controlled trials, treatment of persistent pulmonary hypertension of the newborn (PPHN) by the use of inhaled nitric oxide (iNO) has emerged as an established procedure in neonatology. The situation in premature infants appears to be more complicated than in the term infant. Due to the fact that nitric oxide interferes with platelet aggregation, the risk of intraventricular hemorrhage or its aggravation during iNO therapy is being discussed in a controversial manner. Since most studies are aimed at endpoints like oxygenation parameters, the presently available studies report extremely variable incidences of intraventricular hemorrhages (IVH). Meanwhile two large studies could demonstrate that clinical application of iNO in preterm infants is not associated with an increased incidence of IVH. Further randomized controlled trials of iNO in preterm neonates are highly desirable in order to establish the future role of this therapy and its indications.

Abkürzungen:

BPD Bronchopulmonale Dysplasie

CLD Chronische Lungenerkrankung

ECMO Extrakorporale Membranoxygenierung

FiO2Inspiratorische Sauerstoffkonzentration

iNO Inhalatives Stickstoffmonoxid

IVH Intraventrikuläre Blutung

MAP Mittlerer Atemwegsdruck

OI Oxygenierungsindex

PaO2/PAO2 Arterio-alveolärer Sauerstoffgradient

PPHN Persistierende pulmonale Hypertension des Neugeborenen

ppm Teile per Million

Schlüsselwörter:

Pulmonale Hypertension - inhalatives Stickstoffmonoxid - Frühgeborenes - intraventrikuläre Blutung - Thrombozytenaggregationshemmung - extrakorporale Membranoxygenierung

Key words:

Pulmonary hypertension - inhaled nitric oxide - premature infant - intraventricular hemorrhage - inhibition of platelet aggregation - extracorporeal membrane oxygenation

Literatur

  • 01 Amato  M, de Roche  B, von Muralt  G. Persistent pulmonary hypertension in preterm infants.  Padiatr Padol. 1986;  21 25-30
    Google Scholar
  • 02 Banks  B A, Seri  l, Ischiropoulos  H, Merrill  J, Rychik  J, Ballard  R A. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia.  Pediatrics. 1999;  103 610-618
    Google Scholar
  • 03 Barefield  E S, Karle  V A, Phillips  J B 3rd, Carlo  W A. Inhaled nitric oxide in term infants with hypoxemic respiratory failure.  J Pediatr. 1996;  129 279-286
    Google Scholar
  • 04 Bassenge  E. Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors.  Eur Heart J. 1991;  12 12-15
    Google Scholar
  • 05 Chang  L Y, Graham  J A, Miller  F J, Ospital  J J, Crapo  J D. Effects of subchronic inhalation of low concentrations of nitrogen dioxide. I. The proximal alveolar region of juvenile and adult rats.  Toxicol Appl Pharmacol. 1986;  83 45-61
    Google Scholar
  • 06 Cheung  P Y, Salas  E, Etches  P C, Phillipos  E, Schulz  R, Radomski  M W. Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates.  Lancet. 1998;  351 1181-1182
    Google Scholar
  • 07 Cheung  P Y, Peliowski  A, Robertson  C MT. The outcome of very low birth weight neonates (≤ 1500 g) rescued by inhaled nitric oxide: neurodevelopment in early childhood.  J Pediatr. 1998;  133 735-739
    Google Scholar
  • 08 Christou  H, Magnani  B, Morse  D S, Allred  E N, Van Marter  L J, Wessel  D L, Kourembanas  S. Inhaled nitric oxide does not affect adenosine 5′-diphosphate-dependent platelet activation in infants with persistent pulmonary hypertension of the newborn.  Pediatrics. 1998;  102 1390-1393
    Google Scholar
  • 09 Crow  J P, Beckman  J S. The role of peroxynitrite in nitric oxide-mediated toxicity.  Curr Top Microbiol Immunol. 1995;  196 57-73
    Google Scholar
  • 10 Davidson  D, Barefield  E S, Kattwinkel  J, Dudell  G, Damask  M, Straube  R, Rhines  J, Chang  C T. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicentre study. The I-NO/PPHN Study Group.  Pediatrics. 1998;  101 325-334
    CrossrefPubMedGoogle Scholar
  • 11 Day  R W, Lynch  J M, White  K S, Ward  R M. Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension.  Pediatrics. 1996;  98 698-705
    PubMedGoogle Scholar
  • 12 Finer  N N, Barrington  K J. Nitric oxide in respiratory failure in the newborn infant.  Semin Perinatol. 1997;  21 426-440
    PubMedGoogle Scholar
  • 13 George  T N, Johnson  K J, Bates  J N, Segar  J L. The effect of inhaled nitric oxide on bleeding time and platelet aggregation in neonates.  J Pediatr. 1998;  132 731-734
    PubMedGoogle Scholar
  • 14 Gessler  P, Nebe  T, Birle  A, Mueller  W, Kachel  W. A new side effect of inhaled nitric oxide in neonates and infants with pulmonary hypertension: functional impairment of the neutrophil respiratory burst.  Intensive Care Med. 1996;  22 252-258
    CrossrefPubMedGoogle Scholar
  • 15 Gommers  D, Hartog  A, van't Veen  A, Lachmann  B. Improved oxygenation by nitric oxide is enhanced by prior reaeration with surfactant, rather than positive end-expiratory pressure, in lung-lavaged rabbits.  Crit Care Med. 1997;  25 1868-1873
    PubMedGoogle Scholar
  • 16 Hallman  M, Bry  K, Turbow  R, Waffarn  F, Lappalainen  U. Pulmonary toxicity associated with nitric oxide in term infants with severe respiratory failure.  J Pediatr. 1998;  132 827-829
    PubMedGoogle Scholar
  • 17 Hoehn  T, Krause  M, Hentschel  R. High-frequency ventilation augments the effect of inhaled nitric oxide in persistent pulmonary hypertension of the newborn.  Eur Respir J. 1998;  11 234-238
    CrossrefPubMedGoogle Scholar
  • 18 Hoehn  T, Krause  M. Synergistic effect of high-frequency ventilation and inhaled nitric oxide in the treatment of hypoxemic pulmonary failure in infancy.  Pediatr Pulmonol. 1998;  26 228-230
    CrossrefPubMedGoogle Scholar
  • 19 Hoehn  T, Huebner  J, Paboura  E, Krause  M, Leititis  J U. Effect of therapeutic concentrations of nitric oxide (NO) upon bacterial growth in vitro.  Crit Care Med. 1998;  26 1857-1862
    PubMedGoogle Scholar
  • 20 Hogman  M, Frostell  C, Arnberg  H, Hedenstierna  G. Bleeding time prolongation and NO inhalation.  Lancet. 1993;  341 1664-1665
    PubMedGoogle Scholar
  • 21 Horstman  D J, Frank  D U, Rich  G F. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats.  Anesth Analg. 1998;  86 74-81
    PubMedGoogle Scholar
  • 22 Kinsella  J P, Neish  S R, Shaffer  E, Abman  S H. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn.  Lancet. 1992;  340 819-820
    CrossrefPubMedGoogle Scholar
  • 23 Kinsella  J P, Truog  W E, Walsh  W F, Goldberg  R N, Bancalari  E, Mayock  D E, Redding  G J, deLemos  R A, Sardesai  S, McCurnin  D C, Yoder  B A, Moreland  S G, Cutter  G R, Abman  S H. Randomized, multicentre trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe persistent pulmonary hypertension of the newborn (PPHN).  J Pediatr. 1997;  131 55-62
    PubMedGoogle Scholar
  • 24 Kinsella  J P, Walsh  W F, Bose  C L, Gerstmann  D R, Labella  J J, Sardesai  S, Walsh-Sukys  M C, McCaffrey  M J, Cornfield  D N, Bhutani  V K, Cutter  G R, Baier  M, Abman  S H. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial.  Lancet. 1999;  354 1061-1065
    CrossrefPubMedGoogle Scholar
  • 25 The Franco-Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial.  Lancet. 1999;  354 1066-1071
    CrossrefPubMedGoogle Scholar
  • 26 Mercier  J C, Lacaze  T, Storme  L, Roze  J C, Dinh-Xuan  A T, Dehan  M. Disease-related response to inhaled nitric oxide in newborns with severe hypoxaemic respiratory failure. French Paediatric Study Group of Inhaled NO.  Eur J Pediatr. 1998;  157 747-52
    CrossrefPubMedGoogle Scholar
  • 27 Peliowski  A, Finer  N N, Etches  P C, Tierney  A J, Ryan  C A. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes.  J Pediatr. 1995;  126 450-453
    PubMedGoogle Scholar
  • 28 Putensen  C, Räsänen  J, Lopez  F A, Downs  J B. Continuous positive airway pressure modulates effect of inhaled nitric oxide on the ventilation-perfusion distribution in canine lung injury.  Chest. 1994;  106 1563-1569
    PubMedGoogle Scholar
  • 29 Putensen  C, Räsänen  J, Downs  J B. Effect of endogenous and inhaled nitric oxide on the ventilation-perfusion relationships in oleic-acid lung injury.  Am J Resp Crit Care Med. 1994;  150 330-336
    PubMedGoogle Scholar
  • 30 Puybasset  L, Rouby  J-J, Mourgeon  E, Cluzel  P, Souhil  Z, Law-Koune  J-D, Stewart  T, Devilliers  C, Lu  Q, Roche  S, Kalfon  P, Vicaut  E, Viars  P. Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure.  Am J Resp Crit Care Med. 1995;  152 318-328
    PubMedGoogle Scholar
  • 31 Roberts  J D, Polaner  D M, Lang  P, Zapol  W M. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.  Lancet. 1992;  340 818-819
    CrossrefPubMedGoogle Scholar
  • 32 Roberts  J D, Fineman  J R, Morin  F C 3rd, Shaul  P W, Rimar  S, Schreiber  M D, Polin  R A, Zwass  M S, Zayek  M M, Gross  I, Heymann  M A, Zapol  W M. Inhaled nitric oxide and persistent pulmonary hypertension ofthe newborn.  N Engl J Med. 1997;  336 605-610
    CrossrefPubMedGoogle Scholar
  • 33 Samarna  C M, Diaby  M, Fellahi  J L, Mdhafar  A, Eyraud  D, Arock  M, Guillosson  J J, Coriat  P, Rouby  J J. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome.  Anesthesiology. 1995;  83 56-65
    PubMedGoogle Scholar
  • 34 Sasse  S, Kribs  A, Vierzig  A, Roth  B. A staged protocol for the treatment of persistent pulmonary hypertension of the newborn.  Klin Pädiatr. 1997;  209 301-307
    PubMedGoogle Scholar
  • 35 Saugstad  O D. Inhaled nitric oxide for preterm infants - still an experimental therapy.  Lancet. 1999;  354 1047-1048
    CrossrefPubMedGoogle Scholar
  • 36 Skimming  J W, Bender  K A, Hutchison  A A, Drummond  W H. Nitric oxide inhalation in infants with respiratory distress syndrome.  J Pediatr. 1997;  130 225-230
    PubMedGoogle Scholar
  • 37 Stopfkuchen  H. Pathophysiologic principles relevant for therapeutic procedures in persistent pulmonary hypertension of the newborn.  Klin Pädiatr. 1995;  207 63-67
    PubMedGoogle Scholar
  • 38 Subhedar  N V, Ryan  S W, Shaw  N J. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants.  Arch Dis Child Fetal Neonatal Ed. 1997;  77 F185-F190
    PubMedGoogle Scholar
  • 39 The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure.  N Engl J Med. 1997;  336 597-604
    CrossrefPubMedGoogle Scholar
  • 40 The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia.  Pediatrics. 1997;  99 838-845
    CrossrefPubMedGoogle Scholar
  • 41 van Meurs  K P, Rhine  W D, Asselin  J M, Durand  D J. Response of premature infants with severe respiratory failure to inhaled nitric oxide. Preemie NO Collaborative Group.  Pediatr Pulmonol. 1997;  24 319-323
    CrossrefPubMedGoogle Scholar
  • 42 Varela  A F, Runge  A, Ignano  L J, Chandhuri  G. Nitric oxide and prostacyclin inhibit fetal platelet aggregation: a response similar to that observed in adults.  Am J Obstet Gynecol. 1992;  167 1599-1604
    PubMedGoogle Scholar
  • 43 Watchko  J F. Persistent pulmonary hypertension in a very low birthweight preterm infant.  Clin Pediatr. 1985;  24 592-595
    PubMedGoogle Scholar
  • 44 Wessel  D L, Adatia  I, Van Marter  L J, Thompson  J E, Kane  J W, Stark  A R, Kourembanas  S. Improved Oxygenation in a Randomized Trial of Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn.  Pediatrics. 1997;  100 E7
    PubMedGoogle Scholar

Dr. med. Thomas Hoehn

Klinik für Neonatologie Charité, Campus Virchow-Klinikum

Augustenburger Platz 1

13344 Berlin

Phone: Tel. 030-450 66413

Fax: Fax 030-450 66922

Email: E-mail: thomas.hoehn@charité.de

      >